Literature DB >> 33224741

Association between platelet count and the risk of bleeding among patients with nonvalvular atrial fibrillation taking dabigatran after radiofrequency ablation: a cohort study.

Yurong Xiong1, Wei Zhou2, Minghui Li1, Tao Wang1, Xiao Huang1, Huihui Bao1,2, Xiaoshu Cheng1,2.   

Abstract

BACKGROUND: A reduction in platelet count or function can be a risk factor for bleeding in anticoagulated patients. However, the association between platelet count and the risk of bleeding among nonvalvular atrial fibrillation (NVAF) patients taking dabigatran remains unclear. The aim of this study was to investigate the relationship between platelet count and the risk of bleeding among patients with NVAF taking dabigatran after radiofrequency ablation.
METHODS: In this multicenter, prospective and observational study, a total of 576 NVAF patients treated with dabigatran (110 mg bid) after radiofrequency ablation were recruited from 12 centers in China from February 2015 to December 2017. All patients were followed for 3 months. The association between platelet count and the risk of bleeding was evaluated by Cox proportional hazards regression analysis. To explore the nonlinearity between platelet count and bleeding, we used a Cox proportional hazards regression model with cubic spline functions and smooth curve fitting and a two-piecewise Cox proportional hazards model.
RESULTS: During a median follow-up duration of 87 days, 50 patients experienced bleeding events. Overall, there was an inverse relationship between the risk of bleeding and platelet count. Low platelet count (<100×109/L) were associated with an increased risk of bleeding [hazard ratio (HR), 4.05; 95% confidence interval (CI): 1.32-12.46] compared to normal counts. The adjusted smooth curve showed a nonlinear relationship between platelet count and bleeding events. The inflection point of the platelet count was 105×109/L. For platelet counts <105×109/L, the HR (95% CI) was 0.89 (0.84-0.95), and for platelet counts ≥105×109/L, the HR (95% CI) was 1.01 (0.95-1.08).
CONCLUSIONS: Low platelet counts were associated with an increased risk for bleeding among patients with NVAF taking dabigatran after catheter ablation. 2020 Cardiovascular Diagnosis and Therapy. All rights reserved.

Entities:  

Keywords:  Platelet; atrial fibrillation (AF); bleeding; dabigatran; radiofrequency ablation

Year:  2020        PMID: 33224741      PMCID: PMC7666943          DOI: 10.21037/cdt-20-645

Source DB:  PubMed          Journal:  Cardiovasc Diagn Ther        ISSN: 2223-3652


  23 in total

1.  Factors at admission associated with bleeding risk in medical patients: findings from the IMPROVE investigators.

Authors:  Hervé Decousus; Victor F Tapson; Jean-François Bergmann; Beng H Chong; James B Froehlich; Ajay K Kakkar; Geno J Merli; Manuel Monreal; Mashio Nakamura; Ricardo Pavanello; Mario Pini; Franco Piovella; Frederick A Spencer; Alex C Spyropoulos; Alexander G G Turpie; Rainer B Zotz; Gordon Fitzgerald; Frederick A Anderson
Journal:  Chest       Date:  2010-05-07       Impact factor: 9.410

Review 2.  2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society.

Authors:  Craig T January; L Samuel Wann; Joseph S Alpert; Hugh Calkins; Joaquin E Cigarroa; Joseph C Cleveland; Jamie B Conti; Patrick T Ellinor; Michael D Ezekowitz; Michael E Field; Katherine T Murray; Ralph L Sacco; William G Stevenson; Patrick J Tchou; Cynthia M Tracy; Clyde W Yancy
Journal:  J Am Coll Cardiol       Date:  2014-03-28       Impact factor: 24.094

3.  Clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRAF).

Authors:  Brian F Gage; Yan Yan; Paul E Milligan; Amy D Waterman; Robert Culverhouse; Michael W Rich; Martha J Radford
Journal:  Am Heart J       Date:  2006-03       Impact factor: 4.749

4.  Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT). Italian Study on Complications of Oral Anticoagulant Therapy.

Authors:  G Palareti; N Leali; S Coccheri; M Poggi; C Manotti; A D'Angelo; V Pengo; N Erba; M Moia; N Ciavarella; G Devoto; M Berrettini; S Musolesi
Journal:  Lancet       Date:  1996-08-17       Impact factor: 79.321

5.  Variations in cause and management of atrial fibrillation in a prospective registry of 15,400 emergency department patients in 46 countries: the RE-LY Atrial Fibrillation Registry.

Authors:  Jonas Oldgren; Jeff S Healey; Michael Ezekowitz; Patrick Commerford; Alvaro Avezum; Prem Pais; Jun Zhu; Petr Jansky; Alben Sigamani; Carlos A Morillo; Lisheng Liu; Albertino Damasceno; Alex Grinvalds; Juliet Nakamya; Paul A Reilly; Katalin Keltai; Isabelle C Van Gelder; Afzal Hussein Yusufali; Eiichi Watanabe; Lars Wallentin; Stuart J Connolly; Salim Yusuf
Journal:  Circulation       Date:  2014-01-24       Impact factor: 29.690

6.  Dabigatran versus warfarin in patients with atrial fibrillation.

Authors:  Stuart J Connolly; Michael D Ezekowitz; Salim Yusuf; John Eikelboom; Jonas Oldgren; Amit Parekh; Janice Pogue; Paul A Reilly; Ellison Themeles; Jeanne Varrone; Susan Wang; Marco Alings; Denis Xavier; Jun Zhu; Rafael Diaz; Basil S Lewis; Harald Darius; Hans-Christoph Diener; Campbell D Joyner; Lars Wallentin
Journal:  N Engl J Med       Date:  2009-08-30       Impact factor: 91.245

7.  Thromboembolic, Bleeding, and Mortality Risks of Rivaroxaban and Dabigatran in Asians With Nonvalvular Atrial Fibrillation.

Authors:  Yi-Hsin Chan; Chi-Tai Kuo; Yung-Hsin Yeh; Shang-Hung Chang; Lung-Sheng Wu; Hsin-Fu Lee; Hui-Tzu Tu; Lai-Chu See
Journal:  J Am Coll Cardiol       Date:  2016-09-27       Impact factor: 24.094

8.  Bleeding events and activated partial thromboplastin time with dabigatran in clinical practice.

Authors:  Mihoko Kawabata; Yasuhiro Yokoyama; Tetsuo Sasano; Hitoshi Hachiya; Yasuaki Tanaka; Atsuhiko Yagishita; Koji Sugiyama; Tomofumi Nakamura; Masahito Suzuki; Mitsuaki Isobe; Kenzo Hirao
Journal:  J Cardiol       Date:  2013-05-14       Impact factor: 3.159

9.  Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study.

Authors:  Sumeet S Chugh; Rasmus Havmoeller; Kumar Narayanan; David Singh; Michiel Rienstra; Emelia J Benjamin; Richard F Gillum; Young-Hoon Kim; John H McAnulty; Zhi-Jie Zheng; Mohammad H Forouzanfar; Mohsen Naghavi; George A Mensah; Majid Ezzati; Christopher J L Murray
Journal:  Circulation       Date:  2013-12-17       Impact factor: 29.690

Review 10.  Epidemiology of atrial fibrillation: European perspective.

Authors:  Massimo Zoni-Berisso; Fabrizio Lercari; Tiziana Carazza; Stefano Domenicucci
Journal:  Clin Epidemiol       Date:  2014-06-16       Impact factor: 4.790

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.